MicroPort and Robocath signed a binding term sheet to establish a China-based joint venture to obtain regulatory approval, manufacture, and commercialize Robocath's R-One robotic system in Greater China. MicroPort will invest €5.1 million for 51% stake, Robocath €4.9 million for 49%.
MicroPort Medical announced its subsidiary will invest up to €25.3 million in Robocath, a French vascular robotics company, for a 23.19% stake. The parties also plan to form a joint venture in China to commercialize Robocath's R-One system.
MicroPort Medical (Hong Kong) and SRL (owned by Yunfeng Fund III) agreed to jointly fund the acquisition of LivaNova's CRM business for up to $200 million. MicroPort Hong Kong will hold 75% and SRL 25% of the buyer, MicroPort Cardiac Rhythm B.V.